Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sanofi romania srl - ibuprofenum - comprimate filmate - 400 mg

Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novartis pharma ag - diclofenacum - drajeuri - 50 mg

Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

acino pharma ag - lornoxicamum - comprimate filmate - 8 mg

Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

opella healthcare romania s.r.l. - ibuprofenum - comprimate filmate - 400 mg

Молдавија - Румунски - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

acino pharma ag - lornoxicamum - comprimate filmate - 8 mg

Европска Унија - Румунски - EMA (European Medicines Agency)

ferrer internacional s.a. - loxapine - schizophrenia; bipolar disorder - sistem nervos - adasuve este indicat pentru controlul rapid al agitării ușoare până la moderate la pacienții adulți cu schizofrenie sau tulburare bipolară. pacienții trebuie să primească tratament regulat imediat după controlul simptomelor acute de agitație.

Европска Унија - Румунски - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Молдавија - Румунски - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

neogen corporation, sua - set - -

Европска Унија - Румунски - EMA (European Medicines Agency)

mylan ireland limited - fingolimod clorhidrat de - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 și 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Европска Унија - Румунски - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.